Regeneron anticipates a decline in EYLEA sales ... Recent demand increase of 5% in Q1, though net sales remain flat. - Experienced a 19% global growth and is leading in prescription share.

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

Regeneron Pharmaceuticals got a modest confidence bump as Mirae Asset Global ETFs Holdings added 1,712 shares to their ...

Bayer AG BAYRY reported first-quarter 2025 core earnings of 66 cents per American Depositary Receipt (ADR), beating the Zacks ...

Real-time index price for DJ All Cattle Index (BAC), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Humankind Investments increased its stake in Regeneron Pharmaceuticals by 62.3%, showing rising investor interest despite the ...

Regeneron anticipates a decline in EYLEA sales due to biosimilar ... Recent demand increase of 5% in Q1, though net sales remain flat. - Experienced a 19% global growth and is leading in prescription ...

A jury found Amgen liable for antitrust violations, awarding Regeneron $406.8 million in damages related to Praluent competition. A federal court jury in Delaware has ruled that Amgen Inc ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. The two companies, along with 17 US health ...

The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by Citigroup on May 14, 2025. The analyst firm set a price target for $700.00 expecting REGN to rise to within 12 ...